Be Biopharma Stock

be.bioHealthcareFounded: 2020Funding to Date: $182.1MM

Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. The company's medicines address major hurdles of cell and gene therapies, and are durable, re-disable, and can be administered without toxic conditioning, thereby enabling healthcare sectors and patients to treat diseases like cancer, autoimmune conditions, and an enzyme deficiency. Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute.

Register for Details

For more details on financing and valuation for Be Biopharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Be Biopharma.

Register Today

Be Biopharma investors also invested in these private companies

Ra Capital Management
Alta Partners
Takeda Ventures
Arch Venture Partners

Team

Management Team

Brad Hartman
Chief People Officer
Rick Morgan
Chief Scientific Officer
Lea Hachigian
Co-Founder & VP of Strategy
Joanne Smith-Farrell
Chief Executive Officer
Krishnan Viswanadhan
President & Chief Operating Officer

Board Members

Steven Gillis
Arch Venture Partners

Other companies like Be Biopharma in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$298.33MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$327.39MM
Sector
 
 
Sector
Last Round Est. Valuation
$500MM